Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD33KO-Loop CAR-iNK cells
- Development stage
- Preclinical
- Lead developer
- Beijing Institute of Zoology
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD33KO-Loop CAR-iNK cells are an experimental allogeneic cell therapy consisting of natural killer (NK) cells derived from human induced pluripotent stem cells (iPSCs). These cells are engineered with a bivalent 'Loop CAR' that simultaneously targets CD33 and mesothelin (MSLN), antigens frequently expressed in acute myeloid leukemia (AML). To prevent fratricide (self-killing) caused by the expression of CD33 on the NK cells themselves, the CD33 gene is knocked out using CRISPR/Cas12i technology. This modification enhances the expansion and persistence of the therapeutic cells. The therapy is designed to overcome tumor antigen escape and reduce the toxicities associated with traditional autologous CAR-T therapies, providing a standardized, off-the-shelf immunotherapy product.
- Other names
- CD33KO-CD33-MSLN loop CAR-iNK cellsCD-33KO-CD33-MSLN loop CAR-iNK cellsCD 33KO-CD33-MSLN loop CAR-iNK cellsCD33-deficient Loop CAR-iNK cellsCD-33-deficient Loop CAR-iNK cellsCD 33-deficient Loop CAR-iNK cells
02
Targets
MesothelinCD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on CD33KO-Loop CAR-iNK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD33KO-Loop CAR-iNK cells.